Manufacturing Partnerships NEUVOGEN has built leadership for vaccine manufacturing, signaling readiness to scale production of therapeutic whole cell cancer vaccines. Target contract manufacturers and CDMOs with capabilities in GMP manufacturing, process development, analytical testing, and fill-finish to support the broad pipeline and future commercial scale.

Advisory Credibility The addition of renowned immunotherapy experts to the Scientific Advisory Board strengthens collaboration appeal. Leverage SAB relationships for sponsored research, translational studies, and joint trials to accelerate validation and attract co-development partners.

Pipeline Opportunity A broad whole cell cancer vaccine pipeline across multiple solid tumors opens opportunities for multi-indication co-development or licensing deals. Propose milestone-driven partnerships with shared risk and clear value across indications.

Regional Outreach With a lean team based in San Diego, NEUVOGEN can benefit from regional alliances with CROs, academic centers, and local biotech networks to accelerate clinical development, regulatory strategy, and scalable manufacturing partnerships.

Strategic Positioning The mission-driven focus on leveraging the immune system, coupled with high-profile advisory leadership, makes NEUVOGEN an attractive partner for pharma seeking immuno-oncology platforms. Explore co-development, licensing, and strategic investment discussions around multi-target vaccine strategies.